Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease

Peptides. 2010 Oct;31(10):1866-72. doi: 10.1016/j.peptides.2010.06.033. Epub 2010 Jul 13.

Abstract

Alzheimer's disease (AD) is a devastating degenerative disorder of the brain for which there is no cure or effective treatment. There is much evidence to suggest that β-amyloid protein (Aβ) aggregation in the brain leading to deposits is an important step in the development of AD. Recently, two peptides, RGKLVFFGR (OR1) and RGKLVFFGR-NH(2) (OR2) containing the sequence KLVFF, which is the central region (residues 16-20) of Aβ, have been found to be potent inhibitors of Aβ aggregate formation. Here we report that retro-inversion of these sequences increases efficacy of the peptides in the inhibition of aggregation and toxicity of β-amyloid. We describe the synthesis and inhibitory properties of these retro-inverso peptides.

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / pathology*
  • Amino Acid Sequence
  • Amyloid beta-Peptides / chemistry*
  • Amyloid beta-Peptides / genetics
  • Amyloid beta-Peptides / metabolism*
  • Amyloid beta-Peptides / toxicity
  • Animals
  • Cell Line, Tumor
  • Humans
  • Molecular Sequence Data
  • Neurons / cytology
  • Neurons / drug effects
  • Neuroprotective Agents / chemistry
  • Neuroprotective Agents / metabolism
  • Neuroprotective Agents / therapeutic use
  • Peptide Fragments / toxicity
  • Peptides / chemistry*
  • Peptides / genetics
  • Peptides / metabolism*
  • Peptides / therapeutic use
  • Protein Binding

Substances

  • Amyloid beta-Peptides
  • Neuroprotective Agents
  • Peptide Fragments
  • Peptides
  • amyloid beta-protein (1-40)